Glytec Joins Leapfrog's Committee to Enhance Patient Safety and Diabetes Management

Glytec, a leading software as a service (SaaS) provider specializing in diabetes and insulin management, has announced a new collaborative partnership with The Leapfrog Group through its Partner Advisory Committee (PAC). This partnership aims to enhance patient safety, reduce healthcare costs, and improve inpatient diabetes care outcomes, in alignment with recent reporting requirements set forth by the U.S. Centers for Medicare & Medicaid Services (CMS).

The Leapfrog Group, a national nonprofit organization committed to improving the quality and safety of American healthcare, established the Partners Advisory Committee in 2009. This committee comprises various national and regional health plans, hospital systems, and enterprise vendors that provide advice on key industry trends and collaborate on partner-driven initiatives.

Glytec and The Leapfrog Group are dedicated to increasing the engagement of consumers, healthcare professionals, and organizations in utilizing Leapfrog Hospital Survey results. This data will inform healthcare decisions and quality improvement initiatives.

Through this collaboration, Glytec intends to work closely with industry leaders to develop and implement strategies optimizing inpatient diabetes management, which is expected to yield significant returns on investment (ROI) by reducing costs and increasing the availability of ICU beds.

Diabetes remains a critical health issue in the United States, affecting over 37 million individuals, with many more at risk. Glytec's advanced technology represents a crucial advancement in the management of this prevalent condition. Importantly, more than 30% of hospital patients in the U.S. require insulin therapy to manage high blood sugar levels during their stays. The importance of effective diabetes management in hospitals has been further highlighted by recent hypo- and hyperglycemic hospital reporting mandates introduced by CMS.

Pat Cua, CEO of Glytec, emphasized the broader implications of improving inpatient diabetes care: "Effective management of diabetes during hospitalization can significantly enhance patient outcomes, increase operational efficiency, reduce complications, and improve the overall cost and quality of care. We are proud to partner with The Leapfrog Group to advance patient safety and set a new standard for diabetes care."

The Leapfrog Group has also teamed up with the American Diabetes Association (ADA) to launch the Recognized Leader in Caring for People Living with Diabetes program. This national recognition initiative honors hospitals providing safe and high-quality care to individuals living with diabetes. The application for the 2025 Recognized Leader in Caring for People Living with Diabetes is now open.

Leah Binder, President and CEO of The Leapfrog Group, expressed enthusiasm about the collaboration with Glytec: "We are excited to welcome Glytec to the Partner Advisory Committee. Their expertise in diabetes management and commitment to patient safety will significantly enhance our collaborative efforts to improve cost-effective healthcare delivery. Glytec's participation will offer valuable industry insights that will drive meaningful advancements in patient care."

The Leapfrog Group, established in 2000 by large employers and other purchasers, is dedicated to driving significant improvements in healthcare quality and safety. The organization’s flagship Leapfrog Hospital Survey collects and transparently reports hospital performance, enabling purchasers and consumers to make informed healthcare decisions. The Leapfrog Hospital Safety Grade, another major initiative, assigns letter grades to hospitals based on patient safety records, helping consumers protect themselves and their families from medical errors and accidents.

Glytec's SaaS platform, utilized by over 350 hospitals, supports collaborative diabetes management and insulin dosing. The platform aims to improve patient outcomes, reduce hospital stays, and streamline workflows, delivering a 6-8x ROI. It includes the FDA-cleared, cloud-based Glytec Glucommander® and Command Center suite, which features clinical decision support, workflow alerts, patient monitoring, risk identification, and AI-driven analytics. Glytec is committed to promoting health equity and improving diabetes outcomes from hospital to home.